Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
A. Horwich(Institute of Cancer Research), SP Stenning, Pat Cook(European Organisation for Research and Treatment of Cancer), Ronald de Wit(Erasmus MC), Sophie D. Fosså(Norwegian Cancer Society), R. J. Sylvester, R.T.D. Oliver(St Bartholomew's Hospital), D.P. Dearnaley(Royal Marsden NHS Foundation Trust), M.H. Cullen(European Organisation for Research and Treatment of Cancer), Graham M. Mead(European Organisation for Research and Treatment of Cancer), D.Th. Sleijfer(European Organisation for Research and Treatment of Cancer), P H de Mulder(European Organisation for Research and Treatment of Cancer), Stan B. Kaye(Institute of Cancer Research)
Cited by 334
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers
|UCL Discovery (University College London)|1997|1k